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Introduction and objectives: Although female gender has been
implicated as a risk factor for AAA repair, the etiologies for this gender
difference remains ill defined. We prospectively analyzed variables that
might impact the aneurysm-related morbidity and mortality in women.
Methods: From 2002 to 2009, 2631 consecutive AAA patients
undergoing open surgical and endovascular aneurysm repair (EVAR)
were entered into a registry based on female (n 636, 24%) vs male (n
1995, 76%) gender. Data were prospectively collected and all variables
analyzed.
Results: Of the 2631 AAA patients, both genders were comparable
with respect to demographics with one exception: women had a higher
incidence of COPD (24% vs 15%, P  .05). A higher percentage of
women presented with AAA rupture (14% vs 8%, P  .05). Compared
with men, women undergoing EVAR had a significant higher mortality
(elective EVAR: 3.2% vs 0.9%; emergent EVAR: 27.3% vs 17.2%; all
EVAR: 5.3% vs 1.9%, P  .05), arterial rupture (4.1% vs 1.2%, P  .05),
postoperative bleeding (4.9% vs 2.9%, P .05), lower extremity ischemic
complications (3.5% vs 0.6%, P  .05), ischemic colitis (4.1% vs 1.2%,
P .05), Palmaz stent placement for type I endoleak (16.3% vs 7.2%, P
.05), and mean hospital length of stay (4.1 vs 1.8 days, P  .05). These
gender differences were not significant in the elective and emergent open
surgical groups. At a mean follow-up of 26 months, there were no gender
differences in survival, secondary interventions, or freedom from aneu-
rysm rupture.
Conclusions: A higher percentage of women present with aneurysm
rupture. When treated by endovascular means, in comparison with men,
women have higher procedurally related morbidity of intraoperative arterial
rupture, postoperative bleeding, lower extremity ischemic complications,
ischemic colitis, and type I endoleaks requiring adjunctive procedures. These
findings suggest the need for improvements in stent graft design and EVAR
procedures that are better suited for women.
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Introduction and objectives: This study determined whether high-
dose statin therapy is associated with a reduction in major adverse events
compared with low-dose or moderate-dose, or no statin therapy, after
carotid revascularization.
Methods: A retrospective review was performed of 872 consecutive
carotid endarterectomy (CEA) and carotid artery stenting (CAS) procedures
in 804 patients between January 2003 and March 2009. Patient demograph-
ics, comorbidities, and clinical outcomes were collected. High-dose statin
therapy was defined as atorvastatin, simvastatin, pravastatin, lovastatin, or
fluvastatin at 80 mg/d or rosuvastatin at 20 mg/d starting before or at the
time of the procedure. The composite primary outcome measure was
all-cause mortality, stroke, any reintervention, and recurrent stenosis 70%For restenosis at 1 year (JVS 2010 model) ReferentResults: At the time of carotid revascularization, 216 patients were
taking no statin, 548 were taking a low or moderate dose, and 108 were
taking a high dose of statins. Hypertension, diabetes, coronary artery
disease, peripheral arterial disease, and congestive heart failure were all
significantly more prevalent in the high-dose group. High-dose statins
were associated with a decrease in the incidence of the composite end
point from 19% to 11% (P  .05) compared with no/low-dose statins.
Multivariate analysis showed high-dose statin therapy was protective of
death, stroke, reintervention, or restenosis (OR, 0.41; 95% CI, 0.21-
0.81; P  .01) and was also associated with a 64% reduction in the odds
of death after CEA or CAS (OR, 0.36; 95% CI, 0.15-0.86; P  .02). In
contrast, lower-dose statin therapy was not associated with a reduction in
the odds of any or all of these adverse events.
Conclusions: High-dose statin therapy initiated before carotid revas-
cularization may have a protective effect in reducing the incidence of death,
stroke, reintervention, or recurrent stenosis after CEA and CAS. Further
studies will be needed to confirm these findings.
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Objectives: Completion imaging by duplex or arteriogram after ca-
rotid endarterectomy (CEA) is performed to confirm technical adequacy and
reduce perioperative complications. We examined the utilization of comple-
tion imaging and associated outcomes.
Methods: A retrospective analysis was done of 6261 CEAs performed
in 5749 patients in the multicenter Vascular Study Group of New England.
We categorized surgeons’ use of completion imaging as routine (90% of
CEAs), selective (5%-90%), or rarely (0%-5%). We examined crude and
risk-adjusted 30-day stroke/death and 1-year restenosis rates across these
groups.
Results: Although 91% (5708 of 6261) of CEAs involved a comple-
tion study, 58% were Doppler insonation (3702 of 6261). Completion
imaging was used in 32% of CEAs, consisting of 31% duplex (1981 of
6261) and 1% arteriography (22 of 6261; Table), and resulted in 185
(2.9%) arterial re-explorations. Crude and adjusted 30-day stroke/death
rates were not significantly different across categories of completion
imaging use, but 70% restenosis at 1 year was lower in patients undergo-
ing routine completion imaging (OR, 0.5; 95% CI, 0.27-0.92). Al-
though crude 30-day stroke/death rates were higher in patients under-
going re-exploration based on completion imaging (3.8 vs 1.8%, P 
.049), differences were attenuated when we adjusted for patient charac-
teristics predictive of stroke/death (adjusted OR, 2.2; 95% CI, 0.9-5.5).
A review of 68 patients who underwent arterial re-exploration demon-
strated that technical problems amenable to surgical correction are often
identified, such as intimal flaps (82%), dissection (6%), or flow velocity
abnormalities (6%; Fig). These findings led to intraoperative repair in
96% of re-explorations.
Conclusions: Although completion imaging did not significantly
at 5 years. A multivariate logistic regression model was used for statistical
analysis.
change 30-day stroke/death rates, these studies identify correctible techni-
cal lesions and reduce restenosis at 1 year.
Table. Surgeon practice pattern for use of completion imaging
Variable Rarely Selective Routine P
(0%-5% of CEAs) (5%-90% of CEAs) (90% of CEAs)
Surgeons, No. (%) 35 (49) 16 (22) 20 (28) n/a
Number of CEAs, No. (%) 3412 (54) 1045 (17) 1804 (29) n/a
30-day stroke/death (unadjusted), No. (%) 56/3412 (1.6) 15/1045 (1.4) 45/1804 (2.5) .052
Restenosis 70% at long-term follow-up (unadjusted),
No. (%)
81/1881 (4.1) 13/595 (2.2) 41/1058 (3.9) .062
Adjusted OR (95% CI)
For 30-day stroke/death (JVS 2008 model) Referent 0.8 (0.4-1.4) 1.4 (0.9-2.2) .1060.6 (0.3-1.1) 0.5 (0.3-0.9) .025
